Why Australia’s Dermatology Shortage is Worse Than it Needs to Be

A case study in Professional Boundary Instantiation

Australia needs more dermatologists, but the shortage is amplified by systems that restrict how additional capability can be trained, recognised, organised and funded.

Australia carries one of the highest melanoma burdens in the world. Melanoma is the country’s third most commonly diagnosed cancer, and the wider burden of skin disease extends well beyond melanoma. Yet access to specialist care remains uneven, particularly outside metropolitan areas.

National patient-experience data are not specific to dermatology, but they show the environment in which specialist care operates. In 2024–25, 26.4 per cent of people who saw a medical specialist reported waiting longer than they felt was acceptable, while 8.6 per cent of people who needed specialist care delayed or did not use it because of cost. The barriers were greater for younger people, women and people with long-term health conditions.

The conventional diagnosis is straightforward: Australia needs more dermatologists. That is true. But it is incomplete.

The access problem is also shaped by an institutional architecture that concentrates training, specialist recognition and payment around one narrow pathway, while providing few stable alternatives for defined parts of dermatological care. The result is not simply a shortage of specialists. It is a system that amplifies the effects of that shortage.

“Engineered” does not mean that a single organisation deliberately designed poor access. It describes a structural outcome: scarcity is generated and repeatedly reproduced by the way education, regulation, employment and funding fit together.

The isotretinoin case: a safety rule and an access bottleneck

Oral isotretinoin is a highly effective treatment for severe acne that has not responded to conventional therapy. It also carries serious risks. It is highly teratogenic and requires careful pregnancy-prevention measures; Australian safety information also highlights recognised risks of mood-related and other psychiatric changes. Strong clinical governance is therefore warranted.

Australia manages those risks partly through a prescribing restriction. Under the June 2026 Poisons Standard, oral isotretinoin remains subject to Appendix D controls that limit prescribing to a specialist physician or dermatologist.

The restriction answers the safety question by specifying a professional category. It does not separately ask which practitioners could demonstrate the required knowledge, monitoring capability and governance arrangements. A GP with advanced dermatology expertise cannot prescribe solely on the basis of demonstrated capability. The professional boundary is used as the risk-control mechanism.

That matters because severe acne is not a trivial condition. Delayed treatment can increase the risk of permanent scarring and compound the psychological and social effects of the disease. A restriction intended to protect patients can therefore create a different form of risk when it makes timely treatment difficult to obtain.

New Zealand shows that specialist-only prescribing is not the only safety model

New Zealand widened funded isotretinoin prescribing in 2009 to vocationally registered GPs and nurse practitioners working under Special Authority criteria. The change did not remove safety controls; it shifted the control from specialist identity alone towards an explicit prescribing protocol and practitioner capability.

By 2011–12, more than half of isotretinoin dispensings were being prescribed by GPs. New Zealand medicines-safety monitoring subsequently reported no significant change in the annual pattern of adverse-reaction reports. This does not prove that every practitioner should prescribe isotretinoin or that all outcomes are identical. It does show that specialist-only restriction is not the sole available way to govern the risk.

Australia is now reconsidering the boundary. A proposal considered by the Therapeutic Goods Administration in late 2025 sought to extend prescribing to medical practitioners holding advanced general-practice fellowships. As at June 2026, however, the current Poisons Standard retains the specialist restriction.

Four structures that amplify scarcity

The isotretinoin restriction is the most visible boundary, but it is only one part of the dermatology architecture. Professional Boundary Instantiation identifies four mechanisms through which the settlement is reproduced.

1. Curriculum and training

Dermatology specialist training is necessarily intensive and clinically supervised. Training places depend on accredited settings, available supervisors, hospital infrastructure and government funding, as well as College standards. Each requirement is defensible in isolation. Together, they create a tightly bounded pathway whose capacity is difficult to expand quickly and whose workforce remains heavily concentrated in larger centres.

This is not simply a matter of the College choosing how many dermatologists should exist. Supply emerges from the interaction of accreditation, service capacity, employment funding and supervisory availability. The result is nevertheless a narrow pipeline into a workforce carrying a very large national burden of disease.

2. Regulation and recognised authority

For Australian-trained doctors, specialist recognition in dermatology is ordinarily achieved through Fellowship of the Australasian College of Dermatologists. International specialists may enter through Medical Board pathways that assess their qualifications and comparability. These pathways appropriately protect the specialist title and establish standards for comprehensive specialist practice.

What the system does not provide is a nationally recognised category for a practitioner with a defined partial dermatology scope: for example, a GP with advanced expertise in inflammatory skin disease, an advanced-practice nurse working within a dermatology service, or another practitioner credentialled for a specific component of care. The system recognises general practice and full specialist dermatology, but has limited language for the capability that sits between them.

3. Organisational and industrial recognition

A practitioner can be capable of undertaking work without an employer creating a viable role through which that capability can be used. Public dermatology services are generally organised around specialist dermatologist positions. There are few consistent position descriptions, classifications, governance arrangements or career pathways for practitioners who could complement specialist services within a defined extended scope.

This is not usually a legal prohibition. It is an organisational decision about what roles exist, where accountability sits and which capabilities the employer will recognise. Without an approved role and governance structure, additional capability remains personal expertise rather than deployable workforce capacity.

4. Funding and payment

Medicare recognises dermatology through practitioner categories and item descriptors. Specialist consultations attract specialist rebates; GPs provide and bill substantial volumes of skin-cancer assessment and procedural care through general-practice and procedural items. But there is no coherent national payment pathway for an extended-scope dermatology role sitting between general practice and specialist care.

The Commonwealth’s dermatology workforce analysis found that a relatively small group of high-volume skin-cancer GPs already delivered more billed skin-cancer services than the specialist dermatology workforce. It also found no agreed nationally accredited standard for this emerging area of general-practice subspecialisation. The work has already moved. The architecture has not fully caught up with it.

Funding therefore does more than pay for services. It determines which workforce models are economically viable and which forms of capability remain peripheral. Where payment attaches primarily to practitioner category rather than to the work and governance required, fiscal arrangements reinforce the professional boundary.

Why changing one part is not enough

These mechanisms reinforce one another. Increasing specialist training places is valuable, but it is slow and does not create alternative pathways for work that does not require full specialist expertise. Changing a prescribing restriction can improve access, but its effect will be limited if employers do not create supported roles or if payment arrangements make the model financially unviable. Creating an extended-scope role will not help if there is no recognised credential or referral pathway.

This is reform absorption. A change is achieved in one part of the system, but the unchanged parts limit how far it can travel. The reform is real; its practical effect is smaller than intended because the surrounding architecture still reflects the previous division of work.

This is not an argument for replacing dermatologists

Australia needs more dermatologists, better geographic distribution and stronger public dermatology capacity. Complex, uncertain, high-risk and treatment-resistant conditions require specialist expertise. The purpose of architectural reform is not to weaken that expertise or reduce safety standards.

It is to use scarce specialist capability where it adds the greatest value, while creating safe and recognised pathways for other practitioners to undertake work that falls within their demonstrated competence. A system that requires a dermatologist for every component of dermatological care does not protect specialist value. It turns specialist expertise into a bottleneck.

Why technology will not redesign the system

Artificial intelligence may improve lesion recognition, triage and clinical decision support. It may help GPs identify which patients need urgent specialist input and which can be managed safely in primary care. But technology does not create authorised roles, governance arrangements, career structures or payment pathways.

Even a highly accurate tool cannot decide who is permitted, supported and funded to act on its output. If new technology is layered onto the same referral and payment architecture, it may improve the information entering the system without removing the bottlenecks that determine what happens next.

What architectural reform would look like

A more accessible dermatology system would not rely on one intervention. It would align changes across all four mechanisms.

Training capacity: Expand specialist training and supervisory capacity, particularly outside metropolitan centres, while developing nationally consistent education and credentialling for defined extended-scope roles.
Regulatory and governance pathways: Retain strong specialist standards while creating capability-based pathways for specific areas of practice where the evidence supports safe delegation, substitution or shared care.
Recognised jobs and careers: Create professionally supported roles, position descriptions, clinical-governance arrangements and career pathways through which additional dermatology capability can be used in public and community services.
Payment aligned with the work: Design Medicare and other funding arrangements that recognise the capability, complexity and governance required for the service, rather than relying only on the historical professional category of the practitioner.
Networked specialist support: Use dermatologists as consultants, supervisors and escalation points within broader models of care, allowing specialist expertise to support a larger distributed workforce.

The point is not that all dermatology work has equal complexity or should attract the same payment. It is that the system should be able to distinguish the work that requires specialist dermatology from the work that can be delivered safely through other governed pathways. At present, professional category often performs that sorting function by default.

Conclusion

Australia’s dermatology shortage is real. But its effect on access is magnified by an architecture that concentrates training, authority, organisational recognition and specialist payment around a single narrow pathway.

The isotretinoin case makes the pattern visible. A serious medicine requires strong safeguards. Australia has chosen to express those safeguards largely through specialist identity, even though other jurisdictions have shown that capability-based prescribing under explicit protocols is possible. The same structural pattern appears more broadly in the limited recognition of extended-scope roles and in payment arrangements that have not kept pace with work already moving across professional boundaries.

The reform question is therefore larger than how many dermatologists Australia trains. It is whether every component of dermatological care must continue to pass through the same specialist bottleneck.

Scarce specialist expertise should be protected by using it where it is most needed — not by preventing the health system from recognising and mobilising other safe, qualified capability.

About this case study

This is a worked example in the Professional Boundary Instantiation series at HealthWorX Futures. The parent framework is developed in Working Paper No. 1, Professional Boundary Instantiation: How health systems create workforce scarcity.

Sources and further reading